Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,931,588 papers from all fields of science
Search
Sign In
Create Free Account
delafloxacin
Known as:
1-(6-Amino-3,5-Difluoropyridin-2-Yl)-8-Chloro-6-Fluoro-7-(3-Hydroxyazetidin-1-yl)-4-Oxo-1,4-Dihydroquinoline-3-Carboxylic Acid
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
ABT 492
Narrower (1)
WQ 3034
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BaxdelaTM (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections.
A. Adler
,
Saira B. Chaudhry
,
Tamara Goldberg
P & T : a peer-reviewed journal for formulary…
2018
Corpus ID: 53242270
Baxdela (delafloxacin) for treatment of acute bacterial skin and skin structure infections.
2017
2017
Impact of Delafloxacin (DLX) and Vancomycin/Aztreonam (VAN/AZ) on Resolution of Signs and Symptoms of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
P. Giordano
,
J. Pullman
,
L. Lawrence
,
M. Quintas
,
Carol Tseng
,
S. Cammarata
2017
Corpus ID: 80146444
INTRODUCTION • Baseline demographics of age, gender, race, and ethnicity were similar between treatment arms. Patients were…
Expand
2016
2016
A Global Phase 3 Study of Delafloxacin (DLX) Compared to Vancomycin/Aztreonam (VAN/AZ) in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
L. Lawrence
2016
Corpus ID: 114074585
Delafloxacin is an anionic fluoroquinolone antibiotic with a number of unique properties that may make it useful in the treatment…
Expand
2015
2015
RESULTS OF A GLOBAL PHASE 3 STUDY OF DELAFLOXACIN (DLX) COMPARED TO VANCOMYCIN WITH AZTREONAM (VAN) IN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI)
S. Cammarata
,
J. Gardovskis
,
+4 authors
J. Pullman
2015
Corpus ID: 75676780
INTRODUCTION RESULTS CONCLUSIONS Melinta Therapeutics 203-624-5606 info@melinta.com ID Week 2015 San Diego, CA, USA Oct. 7-11…
Expand
Review
2015
Review
2015
[New antibacterial agents on the market and in the pipeline].
W. Kern
Der Internist
2015
Corpus ID: 34076115
After some years of stagnation there have been several new successful developments in the field of antibacterial agents. Most of…
Expand
2015
2015
A Phase 1, Open-Label, Evaluation of the Single-Dose Pharmacokinetics of Delafloxacin (DLX) in Subjects With and Without Hepatic Impairment
Randall K Hoover
,
M. Quintas
,
L. Lawrence
,
Sriram Gunda
,
E. Sun
,
S. Cammarata
2015
Corpus ID: 75917380
INTRODUCTION RESULTS CONCLUSIONS Melinta Therapeutics 203-624-5606 info@melinta.com ID Week 2015 San Diego, CA, USA Oct. 7-11…
Expand
2015
2015
Neue Antibiotika auf dem Markt und in Entwicklung
W. Kern
Der Internist
2015
Corpus ID: 24249178
ZusammenfassungNach Jahren der Stagnation sind inzwischen wieder zahlreiche Neuentwicklungen im Bereich der antibakteriellen…
Expand
2012
2012
FDA fast-tracks delafloxacin
From Ora Staff Reports
2012
Corpus ID: 74258508
FDA has granted delafloxacin (Rib-X) as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin…
Expand
2012
2012
FDA fast tracks delafloxacin
F. Staff
2012
Corpus ID: 70727110
FDA has granted delafloxacin (Rib-X) as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin…
Expand
2010
2010
Delafloxacin Population Pharmacokinetics and Covariate Exploration
C. Rubino
,
A. Forrest
,
S. Bhavnani
,
E. Burak
,
P. Ambrose
2010
Corpus ID: 123416211
Background: Delafloxacin (DFX) is a broad spectrum quinolone with activity against methicillin-resistant Staphylococcus aureus…
Expand